TNAs, or therapeutic nucleic acids, are nucleic acids or closely related compounds that are used to cure disease. TNAs come in a variety of shapes and sizes, but they all have the same mode of action: sequence specific recognition of endogenous nucleic acids via Watson–Crick base pairing. The growing number of FDA-approved nucleic acid therapies shows that diseases can be treated in vivo by addressing their genetic blueprints. Because they target proteins rather than the underlying reasons, traditional therapies typically have transitory therapeutic results. Nucleic acid treatments, on the other hand, can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. However, delivery strategies that improve stability, enable internalisation, and boost target affinity are required for clinical translation. Synthetic biology, systems biology, computational biology, bioinformatics, and nanotechnology, among other fields, have accelerated progress and established a new paradigm for nucleic acids in therapy.
Title : Study of genetic variation analysis of human TGF-A gene by RFLP Method and estimation of human DNA
Pratik Singh, Amity University Lucknow, India
Title : Protein purification and determination
Divya Yadav, Amity University Lucknow, India
Title : Study of gene expression by RT-PCR
Shazia Syed, Amity University Lucknow, India
Title : Western blotting: Analysis of protein
Misbah Arshad, Amity University Lucknow, India
Title : Study of genetic variation analysis by RFLP
Suraj Kumar Chanda, Amity University Lucknow, India
Title : Qualitative and Quantitative analysis of protein
Shruti Gupta, Amity University Lucknow, India